Lung & Respiratory Breakthroughs: Trelegy Data, EGPA Drug Status, Brensocatib Results & More
In this week’s roundup, we’re diving into five major developments shaping the future of lung and respiratory care—from post-marketing safety data to new funding, orphan drug designations, patent wins, and game-changing clinical trial results.
📊 Trelegy Ellipta Under Review in Korea: Post-marketing surveillance reveals an adverse event rate of 11.36 percent in asthma and 38.61 percent in COPD patients. Regulatory updates expected on May 19.
💰 AATec Medical Raises €4M: Funding fuels clinical prep for ATL-105, a recombinant alpha-1 antitrypsin targeting non-CF bronchiectasis—impacting more than 3 million patients in the West.
🧬 FDA Grants Orphan Drug Status to NS-229: NS Pharma’s JAK1 inhibitor for eosinophilic granulomatosis with polyangiitis (EGPA) secures 7-year exclusivity as Phase 2 trials continue.
📄 Rein Therapeutics Earns U.S. Patents for LTI-03: This synthetic peptide aims to regenerate lung tissue and reduce fibrosis across IPF, ILD, asthma, and COPD. Phase 2 trials expected in H1 2025.
🌍 NEJM Publishes Brensocatib Phase 3 Results: The therapy reduced exacerbations and slowed lung function decline in the largest global bronchiectasis trial. FDA Priority Review underway, with a decision due August 12, 2025.
📢 Stay Ahead in Lung and Respiratory Health Research!
✅ Like, share, and subscribe for weekly updates on lung and respiratory health
#LungHealth #RespiratoryCare #Trelegy #COPD #AsthmaTreatment #Bronchiectasis #OrphanDrug #EGPA #NS229 #Brensocatib #Alpha1Antitrypsin #NCFB #LTI03 #FibrosisTreatment #IPF #ILD #ClinicalTrials #BiopharmaNews #HealthcareInnovation #LucidQuest #InhalationTherapies #PulmonaryUpdates #FDAReview #RespiratoryBreakthroughs #LucidQuestHealth